Litcius/Paper detail

712P CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma

Xizhuang Bai, Y. Chen, X. Zhang, Fan Zhang, Xing Liang, Chunyun ZHANG, Xuming Wang, Bin Lu, Shian Yu, T. Liang

2022Annals of Oncology11 citationsDOI

Topics & Concepts

MedicinePerioperativeApatinibClinical endpointSurgeryHepatocellular carcinomaNeoadjuvant therapyInternal medicineResponse Evaluation Criteria in Solid TumorsAdjuvant therapyAdjuvantRandomized controlled trialOncologyProgressive diseaseChemotherapyCancerBreast cancerHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
712P CAPT: A multicenter randomized controlled trial of perioperative versus postoperative camrelizumab plus apatinib for resectable hepatocellular carcinoma | Litcius